Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease (TRUST-2)
Primary Purpose
Crohn´s Disease
Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
Low dose TSO
Medium dose TSO
High dose TSO
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Crohn´s Disease focused on measuring Crohn´s disease, Trichuris suis, randomized, placebo, induction of remission, porcine whipworm
Eligibility Criteria
Major Inclusion Criteria:
- Signed informed consent,
- Man or woman between 18 and 75 years of age,
- Established diagnosis of Crohn's disease (CD) since at least 3 months prior to screening confirmed by endoscopic and histological, or endoscopic and radiological criteria,
- Negative pregnancy test in females of childbearing potential.
Major Exclusion Criteria:
- Bowel surgery within the last 3 months prior to baseline,
- Resection of more than 50 cm of the ileum,
- Ileostomy or colostomy,
- Septic complications,
- Evidence of infectious diarrhoea (i.e., pathogenic bacteria or Clostridium difficile toxin in stool culture),
- Abscess, perforation, fistulas, or perianal lesions,
- Immediate surgery required (e.g., major stenosis, serious bleeding, peritonitis, ileus),
- Clinical signs of stricturing disease,
- Parenteral or tube feeding,
- Abnormal hepatic function (ALT or ALP > 2.5 x upper limit of normal [ULN] at screening), liver cirrhosis, or portal hypertension,
- Abnormal renal function (Cystatin C > ULN) at screening,
- Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder, which in the opinion of the investigator might have an influence on the patient's compliance or the interpretation of the results,
- Any condition associated with significant immunosuppression,
- Active malignancy or treatment with anticancer drugs during the last 5 years.
- Existing or intended pregnancy or breast-feeding,
- Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial.
Sites / Locations
- Klinikum der Johann Wolfgang Goethe-Universität
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
Low dose TSO
Medium dose TSO
High dose TSO
Placebo
Arm Description
Low dose suspension of TSO
Medium dose suspension of TSO
High dose suspension of TSO
Placebo solution
Outcomes
Primary Outcome Measures
Rate of clinical remission at week 12 (LOCF) defined as a CDAI< 150
Secondary Outcome Measures
Reduction of > 100 points in CDAI
Adverse events
Full Information
NCT ID
NCT01279577
First Posted
January 18, 2011
Last Updated
February 9, 2015
Sponsor
Dr. Falk Pharma GmbH
1. Study Identification
Unique Protocol Identification Number
NCT01279577
Brief Title
Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease
Acronym
TRUST-2
Official Title
Double-blind, Randomised, Placebo-controlled, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Three Different Dosages of Oral Trichuris Suis Ova (TSO) Suspension in Active Crohn's Disease
Study Type
Interventional
2. Study Status
Record Verification Date
February 2015
Overall Recruitment Status
Completed
Study Start Date
November 2010 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
February 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dr. Falk Pharma GmbH
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study will run in centers in Germany, Denmark, Austria, Czech Republic, and Switzerland, only.
This proof-of-concept study aims to evaluate the efficacy of three doses of oral TSO suspension vs. placebo for the induction of remission in Crohn's disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Crohn´s Disease
Keywords
Crohn´s disease, Trichuris suis, randomized, placebo, induction of remission, porcine whipworm
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
254 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low dose TSO
Arm Type
Experimental
Arm Description
Low dose suspension of TSO
Arm Title
Medium dose TSO
Arm Type
Experimental
Arm Description
Medium dose suspension of TSO
Arm Title
High dose TSO
Arm Type
Experimental
Arm Description
High dose suspension of TSO
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo solution
Intervention Type
Drug
Intervention Name(s)
Low dose TSO
Intervention Description
Low dose TSO suspension
Intervention Type
Drug
Intervention Name(s)
Medium dose TSO
Intervention Description
Medium dose TSO suspension
Intervention Type
Drug
Intervention Name(s)
High dose TSO
Intervention Description
High dose TSO suspension
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo solution
Primary Outcome Measure Information:
Title
Rate of clinical remission at week 12 (LOCF) defined as a CDAI< 150
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Reduction of > 100 points in CDAI
Time Frame
12 weeks
Title
Adverse events
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Major Inclusion Criteria:
Signed informed consent,
Man or woman between 18 and 75 years of age,
Established diagnosis of Crohn's disease (CD) since at least 3 months prior to screening confirmed by endoscopic and histological, or endoscopic and radiological criteria,
Negative pregnancy test in females of childbearing potential.
Major Exclusion Criteria:
Bowel surgery within the last 3 months prior to baseline,
Resection of more than 50 cm of the ileum,
Ileostomy or colostomy,
Septic complications,
Evidence of infectious diarrhoea (i.e., pathogenic bacteria or Clostridium difficile toxin in stool culture),
Abscess, perforation, fistulas, or perianal lesions,
Immediate surgery required (e.g., major stenosis, serious bleeding, peritonitis, ileus),
Clinical signs of stricturing disease,
Parenteral or tube feeding,
Abnormal hepatic function (ALT or ALP > 2.5 x upper limit of normal [ULN] at screening), liver cirrhosis, or portal hypertension,
Abnormal renal function (Cystatin C > ULN) at screening,
Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder, which in the opinion of the investigator might have an influence on the patient's compliance or the interpretation of the results,
Any condition associated with significant immunosuppression,
Active malignancy or treatment with anticancer drugs during the last 5 years.
Existing or intended pregnancy or breast-feeding,
Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jürgen Schölmerich, Prof.
Organizational Affiliation
Klinikum der Johann Wolfgang Goethe-Universität
Official's Role
Principal Investigator
Facility Information:
Facility Name
Klinikum der Johann Wolfgang Goethe-Universität
City
Frankfurt a.M.
State/Province
Hessen
ZIP/Postal Code
60590
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease
We'll reach out to this number within 24 hrs